A5055636150- Regulation of Appetite and Obesity
- Adipose Tissue and Metabolism
- Biochemical Analysis and Sensing Techniques
- Receptor Mechanisms and Signaling
- Neurotransmitter Receptor Influence on Behavior
- Neuropeptides and Animal Physiology
- Biochemical effects in animals
- Heart Rate Variability and Autonomic Control
- Memory and Neural Mechanisms
- Metabolism, Diabetes, and Cancer
- Diabetes Treatment and Management
- Neural dynamics and brain function
- Pharmacology and Obesity Treatment
- Olfactory and Sensory Function Studies
- Pancreatic function and diabetes
- Eating Disorders and Behaviors
- Alcohol Consumption and Health Effects
University of Gothenburg
2020-2024
Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with use disorder (AUD). However, the probability of low semaglutide doses, an agonist higher potency affinity for GLP-1R, attenuate alcohol-related responses underlying neuronal mechanisms is unknown.In intermittent access model, we examined ability decrease intake block relapse-like drinking, as well imaging binding fluorescently marked nucleus accumbens (NAc)...
The gut-brain peptide ghrelin and its receptor are established as a regulator of hunger reward-processing. However, the recently recognized inverse agonist, liver-expressed antimicrobial 2 (LEAP2), is less characterized. present study aimed to elucidate LEAP2s central effect on reward-related behaviors through feeding mechanism. LEAP2 was administrated centrally in mice effectively reduced intake palatable foods. Strikingly, correlated preference food. Further, rewarding memory high foods,...
Preclinical studies have identified glucagon-like peptide-1 receptor (GLP-1R) agonists, and the antismoking agents varenicline bupropion as tentative for treatment of alcohol use disorder (AUD). Combining different medications is a recent approach that has gained attention regarding heterogenous difficult-to-treat diseases, like AUD. Successfully, this been tested combination it prevents relapse to drinking in rats. However, assessing effects semaglutide, an FDA-approved GLP-1R agonist...
Abstract The mechanisms contributing to alcohol use disorder (AUD) are complex and the orexigenic peptide ghrelin, which enhances reward, is implied as a crucial modulator. major proportion of circulating ghrelin however non-octanoylated form des-acyl (DAG), whose role in reward processes unknown. As recent studies show that DAG decreases food intake, we hypothesize attenuates alcohol-related responses animal models. Acute repeated treatment dose-dependently decreased drinking male female...
Besides food intake reduction, activation of the amylin pathway by salmon calcitonin (sCT), an and receptor agonist, inhibits alcohol-mediated behaviors in rodents. This involves brain areas processing reward, i.e. laterodorsal (LDTg), ventral tegmental area (VTA) nucleus accumbens (NAc). However, effects stimulation on caused cocaine involved these processes have not yet been investigated. We therefore explored male mice, systemic administration sCT cocaine-induced locomotor stimulation,...
Abstract Rationale Amylin receptors consist of the calcitonin receptor (CTR) and one three activity-modifying proteins (RAMPs). The identification amylin in areas processing reward, namely laterodorsal tegmental area (LDTg), ventral (VTA), nucleus accumbens (NAc), has attributed them a role as reward regulators. Indeed, acute activation by agonist salmon (sCT) attenuates alcohol-induced behaviours rodents. Objectives effects long-term administration sCT on alcohol-related molecular...
The behavioural responses to nicotine involve appetite-regulatory hormones; however, the effects of anorexigenic hormone amylin on reward-related behaviours induced by remain be established. Previous studies have shown that amylinergic pathway regulates alcohol, amphetamine and cocaine. Here, we evaluated salmon calcitonin (sCT), an receptor (CTR) agonist, nicotine-induced locomotor stimulation sensitisation as well dopamine release in nucleus accumbens (NAc) shell. Moreover, investigated...
Abstract The gut-brain peptide ghrelin and its receptor (GHSR) are established as a regulator of hunger reward-processing. However, the recently recognized GHSR inverse agonist, liver-expressed antimicrobial 2 (LEAP2), is less characterized. Given role in many central processes, particular reward, understanding effects LEAP2 high interest to understand reward-related behaviors disorders, including hedonic feeding eating disorders. present study aimed elucidate LEAP2s effect on through...
<title>Abstract</title> The underlying neurobiology of alcohol use disorder (AUD) is complex and needs further unraveling, with one the key mechanisms being gut-brain peptide ghrelin its receptor (GHSR). However, additional substrates pathway, such as liver-expressed antimicrobial 2 (LEAP2), an endogenous GHSR inverse agonist, may contribute to this neurobiological framework. While LEAP2 modulates feeding reward through central mechanisms, effects on responses are unknown. aim present study...
Background and Purpose The limited effectiveness of current pharmacological treatments for alcohol use disorder (AUD) highlights the need novel therapies. These may involve glucagon‐like peptide‐1 receptor or amylin receptor, as treatment with agonists targeting either these receptors lowers intake. complexity mechanisms underlying AUD indicates that combining agents could enhance efficacy. While a combination GLP‐1 reduced food intake body weight synergistic‐like, its influence on is...
Abstract Objective: Combining different pharmaceuticals may be beneficial when treating disorders with complex neurobiology, including alcohol use disorder (AUD). The gut-brain peptides amylin and GLP-1 of potential interest as they individually reduce intake in rodents. While the combination receptor (AMYR) glucagon-like peptide-1 (GLP-1R) agonists have been found to decrease feeding body weight obese male rats synergistically, their combined impact on is unknown. Methods: Therefore, effect...
The glucagon-like peptide 1 receptor (GLP-1R) has recently emerged as a viable candidate target to treat alcohol use disorder (AUD) its agonists have previously shown prevent alcohol-related responses in rodents and reduce drinking overweight patients with AUD. Here, the long-acting GLP-1R agonist semaglutide was investigated on ability relapse both male female rats. Given that alcohol-induced reward driven by dopamine release nucleus accumbens (NAc) influences drinking, hypothesis inhibits...